Company name: Octarine Bio
Description: Developer of cannabinoids and psilocybin derivatives intended to improve the health and well-being of people. The company harnesses synthetic biology using its biosynthetic platform to develop functionally superior cannabinoids and psychedelic tryptamine derivatives, enabling healthcare institutions to treat neurological and psychological disorders.
Year founded: 2018
Industry: Healthcare | Group: | Code:
Start up capital raised (USD Million):
Business status: Startup
Ownership: Privately Held (backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: The company raised an undisclosed amount of seed funding from Vækstfonden on March 11, 2020. The funds will be used for research and seveopment.
Number of active investors:
Profile last updated: 15-Apr-2020
Last known valuation:
Last known valuation date: